Hysterectomy Clinical Trials

Clinical trials related to Hysterectomy Procedure

The Impact of the Continuous Infusion of Intraperitoneal Analgesics on Postoperative Pain After Minimally Invasive Hysterectomy: a Randomized Controlled Trial

Who is this study for? Women undergoing minimally invasive hysterectomy
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The study is a prospective, double-blinded, placebo-controlled multi-center trial to measure if postoperative pain and the amount of narcotics used are reduced by a clinically significant amount in women undergoing minimally invasive hysterectomy receiving a continuous infusion of intraperitoneal (IP) local anesthetic (LA) or a continuous infusion of LA combined with an NSAID compared with a control group who receives only 0.9% normal saline.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

• Hysterectomy planned for a benign gynecologic reason (no evidence of, or concern for, malignancy in the cervix, uterus, tubes or ovaries. Benign gynecologic reasons to have a hysterectomy include fibroids, abnormal uterine bleeding, endometriosis, and pelvic pain.)

• Patient is scheduled to have surgery with a fellowship trained minimally invasive gynecologic surgeons at one of the study sites.

• Patient is planned for a robotic assisted total laparoscopic hysterectomy (RA-TLH) or a total laparoscopic hysterectomy (TLH).

• Patient is capable of informed consent.

• Patient is capable of completing the questionnaires.

Locations
United States
Washington, D.c.
MedStar Washington Hospital Center
RECRUITING
Washington D.c.
The GW Medical Faculty Associates
RECRUITING
Washington D.c.
Contact Information
Primary
Radwa Aly
raly@mfa.gwu.edu
202 677 6209
Time Frame
Start Date: 2019-09-30
Estimated Completion Date: 2026-12
Participants
Target number of participants: 120
Treatments
Experimental: Ropivacaine
Subjects will receive a continuous intraperitoneal infusion of ropivacaine
Experimental: Ropivacaine + Ketorolac
Subjects will receive a continuous intraperitoneal infusion of ropivacaine + ketorolac
Placebo_comparator: Normal Saline
Subjects will receive a continuous intraperitoneal infusion of normal saline
Related Therapeutic Areas
Sponsors
Leads: Ying Liu
Collaborators: Avanos Medical

This content was sourced from clinicaltrials.gov